Stenabolic (SR9009) is a PPAR alpha modifier drug that is still in development as of 2015. Its creator is professor Thomas Burris of the Scripps research institute. Interestingly, it is sold as a SARM and research chemical, and it can be compared to Cardarine (GW-501516), as it is also an agonist of Rev-ErbA. According to an article by “National Medicine,” it enhances exercise capacity in mice by increasing mitochondria in skeletal muscle. This is why it has been marketed and hyped around the internet as “exercise in a bottle.
The drug was developed by Professor Thomas Burris, who found that it was able to reduce obesity in populations of mice. It binds to and activates a protein called Rev-ErbAα, which influences fat and sugar burning in the liver, production of fat cells, and the body's inflammatory response.
A drug known as SR9009, which is currently under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice. Treated mice become lean, develop larger muscles and can run much longer distances simply by taking SR9009, which mimics the effects of aerobic exercise. If similar effects can be obtained in people, the reversal of obesity, metabolic syndrome, and perhaps Type-II diabetes might be the very welcome result.
SR9009 and Endurance
Half of the mice studied showed improved running endurance in terms of both time and distance. SR9009 has been shown to considerably boost exercise endurance in animal models. Scientists think these discoveries may lead to improved cures for individuals suffering from illnesses that severely limit exercise endurance such as obesity, COPD (chronic obstructive pulmonary disease), congestive heart failure and also in the deterioration of muscle capacity linked with aging.
SR9009 and bodybuilding
SR9009 may cause a major breakthrough in fitness.
Recent research show that activation of Rev-erbα with SR9009 resulted to enhanced metabolic activity in skeletal muscle tissue in both culture and in mice. Rev-erbα affects muscle cells by stimulating both the formation of new mitochondria and the authorization of those mitochondria that are flawed.
If the effects of SR9009 on mice can securely be duplicated for people, the new drug may provide new treatments for obesity and its companions, metabolic syndrome and diabetes. Another area in which SR9009 or a similar drug may present significant benefit is to balance the loss of overall muscle conditioning which transpires as a side effect of reduced activity due to sickness or old age.
SR9009 and fat loss
SR9009 was found to be capable of reducing obesity in animal models, particularly mice. SR9009 which is an easy-to-dose oral compound can increase the level of metabolic activity in skeletal muscle of mice. The treated mice became lean, developed larger muscles and had a 50% increase in running abilities which imitates the effects of aerobic exercise.SR9009, however, isn’t like appetite suppressants, laxatives, or “fat blockers.” And you won’t find SR9009 in the ingredient lists of protein powders or exercise supplements.
The difference between SR9009 and other diet pills is in its chemistry. SR9009 is not an appetite suppressant-as many weight-loss drugs are-and directly works by increasing the metabolic rate of muscle.
China
